Supernus Pharmaceuticals Financial Overview
Supernus Pharmaceuticals's market cap is currently $2.70B. The company's EPS TTM is $1.005; its P/E ratio is ―; Supernus Pharmaceuticals is scheduled to report earnings on November 4, 2025, and the estimated EPS forecast is $0.39. See an overview of income statement, balance sheet, and cash flow financials.
